No Evidence of Increased Risk of Acquired Rifampin Resistance
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
No evidence of increased risk of acquired rifampin resistance.
CMAJ. 2020; 192(9):E222.
PMID: 32122981 PMC: 7055942. DOI: 10.1503/cmaj.200235.
References
1.
Diallo T, Adjobimey M, Ruslami R, Trajman A, Sow O, Baah J
. Safety and Side Effects of Rifampin versus Isoniazid in Children. N Engl J Med. 2018; 379(5):454-463.
DOI: 10.1056/NEJMoa1714284.
View
2.
Gegia M, Winters N, Benedetti A, van Soolingen D, Menzies D
. Treatment of isoniazid-resistant tuberculosis with first-line drugs: a systematic review and meta-analysis. Lancet Infect Dis. 2016; 17(2):223-234.
DOI: 10.1016/S1473-3099(16)30407-8.
View
3.
Balcells M, Thomas S, Godfrey-Faussett P, Grant A
. Isoniazid preventive therapy and risk for resistant tuberculosis. Emerg Infect Dis. 2006; 12(5):744-51.
PMC: 3374455.
DOI: 10.3201/eid1205.050681.
View
4.
Menzies D, Long R, Trajman A, Dion M, Yang J, Al Jahdali H
. Adverse events with 4 months of rifampin therapy or 9 months of isoniazid therapy for latent tuberculosis infection: a randomized trial. Ann Intern Med. 2008; 149(10):689-97.
DOI: 10.7326/0003-4819-149-10-200811180-00003.
View
5.
Ahmad N, Ahuja S, Akkerman O, Alffenaar J, Anderson L, Baghaei P
. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet. 2018; 392(10150):821-834.
PMC: 6463280.
DOI: 10.1016/S0140-6736(18)31644-1.
View